# Leica Biosystems

Leica Biosystems is an Asset Manager based in Nussloch, Germany, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Nussloch, Germany, United States
- **Region:** North America
- **Address:** St. Louis, MO, United States
- **Founded:** 1872
- **Assets under management:** Undisclosed
- **Website:** leicabiosystems.com
- **LinkedIn:** https://www.linkedin.com/company/leica-biosystems

## Regulatory record

- **Reports private funds:** No

## About

Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis.

## Sectors

- Healthcare Services
- Digital Health
- AI/ML
- Medical Devices

## People

- Koichi Ohshima — Professor, Department of Pathology, Kurume University
- Sylvia L. Asa — Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center

## Questions

### What is the commercial relationship between Leica Biosystems and Danaher?

Leica Biosystems operates as a Danaher operating company. Since being acquired by Danaher (now part of a larger science and technology conglomerate), Leica Biosystems benefits from Danaher's capital, R&D infrastructure, and regulatory expertise, which allows it to scale its pathology workflow solutions globally.

### What investment stages and asset classes does Leica Biosystems target?

Leica Biosystems does not act as an external investor; it is a Danaher operating company that develops, manufactures, and sells anatomic pathology products and diagnostics. Its focus is on developing instruments, consumables, software, and AI tools for cancer diagnostics.

### How does Leica Biosystems source and develop its AI pathology tools?

Leica Biosystems develops some AI tools internally and partners with third-party developers through its Aperio AI Store. In 2026, the firm signed a global reseller agreement with Mindpeak to expand access to AI pathology solutions. The firm also collaborates with pharmaceutical companies like AstraZeneca and Daiichi Sankyo to develop AI-powered companion diagnostics.

### What is the geographic footprint of Leica Biosystems?

The firm has a global presence with over 3,000 experts worldwide. Headquarters are in St. Louis, USA, with significant operations in Europe (Newcastle, UK) and Asia. Reference customers include institutions in Japan (Kurume University) and the United States (University Hospitals Cleveland Medical Center).

### Does Leica Biosystems participate in external fund commitments or direct investments?

No. Leica Biosystems is a Danaher operating company focused on developing and selling pathology equipment, consumables, and digital solutions. It does not function as an investment entity or asset manager.

### How is Leica Biosystems related to the Mindpeak reseller agreement announced in 2026?

Leica Biosystems and Mindpeak entered a global reseller agreement in 2026, allowing Leica to distribute Mindpeak's AI pathology software through its Aperio AI Store platform. This expands the AI tools available to Leica's customers within a single interface.

## Related profiles

- [Interpublic Group](https://altss.com/profile/interpublic-group)
- [Groupe Cofina](https://altss.com/profile/groupe-cofina)

---

Last updated: 2026-07-09T01:11:15.793Z

Canonical page: https://altss.com/profile/leica-biosystems

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology